Health-related quality of life and psychological distress among patients with type 2 diabetes using semaglutide
DOI:
https://doi.org/10.18203/2320-6012.ijrms20262169Keywords:
Diabetes mellitus type 2, Health related quality of life, SemaglutideAbstract
Background: Semaglutide is increasingly used for type 2 diabetes mellitus (T2DM), but its real-world association with health-related quality of life (HRQoL) and psychological wellbeing remains underexplored in Saudi Arabia. The study aims to assess HRQoL and psychological distress among patients with T2DM according to current semaglutide use.
Methods: This analytical cross-sectional study included 349 adults with T2DM attending outpatient diabetic clinics in Taif, Saudi Arabia, between September 2025 and February 2026. HRQoL was assessed using the Arabic EQ-5D-5L, including EQ-5D-5L index and EQ-VAS scores, while psychological distress was assessed using the Arabic PHQ-4. Adjusted regression models examined associations between semaglutide use and study outcomes.
Results: Among 349 participants, 145 were semaglutide users and 204 were non-users. Semaglutide use was not significantly associated with EQ-VAS score (B=-0.091, 95% CI: -2.259 to 2.078, p=0.935) or EQ-5D-5L index score (B=-0.030, 95% CI: -0.062 to 0.003, p=0.072). However, semaglutide use was associated with higher odds of pain/discomfort (OR=2.610, 95% CI: 1.385-4.917, p=0.003), anxiety/depression (OR=2.175, 95% CI: 1.213-3.899, p=0.009), and any psychological distress (OR=2.929, 95% CI: 1.503–5.710, p=0.002).
Conclusions: Semaglutide use was not associated with better overall HRQoL, but was associated with higher odds of pain/discomfort and psychological distress. Longitudinal studies are needed to clarify whether these associations reflect treatment effects, baseline patient complexity, or unmeasured clinical factors.
References
International Diabetes Federation. Saudi Arabia. Available at: https://idf.org/our-network/regions-and-members/middle-east-and-north-africa/members/saudi-arabia/. Accessed on 26 April 2026.
American Diabetes Association. American Diabetes Association releases Standards of Care in Diabetes-2026. Available at: https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2026. Accessed on 26 April 2026.
ElSayed NA, McCoy RG, Aleppo G, Bajaj M, Balapattabi K, Beverly EA, et al. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1):S59-85.
EuroQol Research Foundation. EQ-5D-5L User Guide. Rotterdam, the Netherlands; 2019. Available at: https://euroqol.org/wp-content/uploads/2023/11/EQ-5D-5LUserguide-23-07.pdf. Accessed on 26 April 2026.
Bilbao-González A, González-Sáenz de Tejada M, Ferrer M, Ramallo-Fariña Y, Paja-Fano M, García-Forero C, et al. Psychometric properties of the EQ-5D-5L in diabetes mellitus patients in Spain. J Patient Rep Outcomes. 2025;9(1):60.
Jankowska A, Młyńczak K, Golicki D. Validity of EQ-5D-5L health-related quality of life questionnaire in self-reported diabetes: evidence from a general population survey. Health Qual Life Outcomes. 2021;19(1):138.
EuroQol Research Foundation. Value sets for scoring the EQ-5D. Available at: https://euroqol.org/information-and-support/resources/value-sets/. Accessed on 26 April 2026.
Al-jedai A, Almudaiheem H, Al-Salamah T, Aldosari M, Almutairi AR, Almogbel Y, et al. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study. Value in Health. 2024;27(5):552-61.
Al Sayah F, Jin X, Short H, McClure NS, Ohinmaa A, Johnson JA. A Systematic Literature Review of Important and Meaningful Differences in the EQ-5D Index and Visual Analog Scale Scores. Value in Health. 2025;28(3):470-6.
Yang K, Fang Y, He J, Li J. Prevalence and risk factors of depression in patients with diabetes mellitus: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:1660478.
Alwhaibi M. Depression, Anxiety, and Health-Related Quality of Life in Adults with Type 2 Diabetes. J Clin Med. 2024;13(20):6028.
Kroenke K, Spitzer RL, Williams JBW, Lowe B. An Ultra-Brief Screening Scale for Anxiety and Depression: The PHQ-4. Psychosomatics. 2009;50(6):613-21.
Ghaheri A, Omani-Samani R, Sepidarkish M, Hosseini M, Maroufizadeh S. The Four-item Patient Health Questionnaire for Anxiety and Depression: A Validation Study in Infertile Patients. Int J Fertil Steril. 2020;14(3):234-9.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Eng J Med. 2016;375(19):1834-44.
Jódar E, Michelsen M, Polonsky W, Réa R, Sandberg A, Vilsbøll T, et al. Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk. Diabetes Obes Metab. 2020;22(8):133-47.
Bekairy AM, Bustami RT, Almotairi M, Jarab A, Katheri AM, Aldebasi TM, et al. Validity and reliability of the Arabic version of the the EuroQOL (EQ-5D). A study from Saudi Arabia. Int J Health Sci (Qassim). 2018;12(2):16-20.
AlHadi AN, AlAteeq DA, Al-Sharif E, Bawazeer HM, Alanazi H, AlShomrani AT, et al. An arabic translation, reliability, and validation of Patient Health Questionnaire in a Saudi sample. Ann Gen Psychiatry. 2017;16(1):32.
Ernstsson O, Burström K, Heintz E, Mølsted Alvesson H. Reporting and valuing one’s own health: a think aloud study using EQ-5D-5L, EQ VAS and a time trade-off question among patients with a chronic condition. Health Qual Life Outcomes. 2020;18(1):388.
Bilbao-González A, González-Sáenz de Tejada M, Ferrer M, Ramallo-Fariña Y, Paja-Fano M, García-Forero C, et al. Psychometric properties of the EQ-5D-5L in diabetes mellitus patients in Spain. J Patient Rep Outcomes. 2025;9(1):60.
Amaama LA, Osei GN, Okyere P, Opoku VO, Yankey TJ, Attoh T, et al. Health‐related quality of life of type 2 diabetes mellitus patients: A cross‐sectional study in the cape coast metropolis. Health Sci Rep. 2024;7(2):e1937.
Rubino D, Bjorner JB, Rathor N, Sharma AM, von Huth Smith L, Wharton S, et al. Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the 1-4 trials. Diabetes Obes Metab. 2024;26(7):2945-55.
Menoth Mohan D, Al Anouti F, Kohli N, Khalaf K. Association of obesity with musculoskeletal health and functional mobility in females-a systematic review. Int J Obes. 2025;49(11):2184-205.
Garcia MM, Corrales P, Huerta MÁ, Czachorowski MJ, López-Miranda V, Medina-Gómez G, et al. Adults with excess weight or obesity, but not with overweight, report greater pain intensities than individuals with normal weight: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024;15:1340465.
Novo Nordisk. Ozempic prescribing information. 2025. Available at: https://www.ozempic.com/prescribing-information.html. Accessed on 26 April 2026.
Wojujutari Ajele K, Sunday Idemudia E. The role of depression and diabetes distress in glycemic control: A meta-analysis. Diabetes Res Clin Pract. 2025;221:112014.
U.S. Food and Drug Administration. Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. 2024. Available at: https://www.fda.gov/drugs/drug-safety-communications/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type. Accessed on 26 April 2026.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Eng J Med. 2023;389(24):2221-32.
Downloads
Published
How to Cite
Issue
Section
